B. Hanstein

Heinrich-Heine-Universität Düsseldorf, Düsseldorf, North Rhine-Westphalia, Germany

Are you B. Hanstein?

Claim your profile

Publications (27)59.68 Total impact

  • P. Dall, B. Hanstein, D.S. Mosny
    [show abstract] [hide abstract]
    ABSTRACT: Mammographisch suspekte, klinisch okkulte Befunde der Mamma sind einer exakten Lokalisation und eindeutigen Diagnosesicherung Mammographisch suspekte, klinisch okkulte Befunde der Mamma sind einer exakten Lokalisation und eindeutigen Diagnosesicherung oft schwer zugänglich, da die konventionelle Nadel-Draht-Markierung häufig nicht optimal gelingt. Folge sind zum einen unnötig oft schwer zugänglich, da die konventionelle Nadel-Draht-Markierung häufig nicht optimal gelingt. Folge sind zum einen unnötig große Gewebedefekte, zum anderen frustrane Exstirpationsversuche. Die digitale Mammographie ermöglicht die Durchführung stereotaktischer große Gewebedefekte, zum anderen frustrane Exstirpationsversuche. Die digitale Mammographie ermöglicht die Durchführung stereotaktischer Biopsieverfahren, bei welchen durch Stereo-MG-Aufnahmen aus 2 verschiedenen Ebenen dem suspekten Herd ein Koordinatenpunkt Biopsieverfahren, bei welchen durch Stereo-MG-Aufnahmen aus 2 verschiedenen Ebenen dem suspekten Herd ein Koordinatenpunkt zugeordnet wird, an welchem sich die integrierte Biopsiemessereinheit orientiert und das Gewebe exstirpiert. Die geschieht zugeordnet wird, an welchem sich die integrierte Biopsiemessereinheit orientiert und das Gewebe exstirpiert. Die geschieht “en bloc” mittels ABBI-System oder in Einzelfragmenten mittels Vakkumbiopsiesystemen (Mammotome oder MIBB). Alle stereotaktischen “en bloc” mittels ABBI-System oder in Einzelfragmenten mittels Vakkumbiopsiesystemen (Mammotome oder MIBB). Alle stereotaktischen Verfahren erfassen millimetergenau den suspekten Herd und schonen somit maximal das umliegende Gewebe. Ein stationärer Aufenthalt Verfahren erfassen millimetergenau den suspekten Herd und schonen somit maximal das umliegende Gewebe. Ein stationärer Aufenthalt wird vermieden. Der minimal-invasive Zugang ermöglicht ein ansprechendes kosmetisches Resultat. Die Summe der letztgenannten wird vermieden. Der minimal-invasive Zugang ermöglicht ein ansprechendes kosmetisches Resultat. Die Summe der letztgenannten Faktoren bedingt eine hohe Akzeptanz bei den betroffenen Patientinnen. Faktoren bedingt eine hohe Akzeptanz bei den betroffenen Patientinnen. Non-palpable breast-lesions like microcalcifications often fail an exact diagnosis. Accurate treatment is difficult by conventional Non-palpable breast-lesions like microcalcifications often fail an exact diagnosis. Accurate treatment is difficult by conventional marking and operating procedures since freehand positionin of al localization wire is often suboptimal. The consequences are marking and operating procedures since freehand positionin of al localization wire is often suboptimal. The consequences are larger tissue-defects leading to an insufficient cosmetic result. Nevertheless, resection of microcalcifications by conventional larger tissue-defects leading to an insufficient cosmetic result. Nevertheless, resection of microcalcifications by conventional surgery remains sometimes incomplete. Digital mammography coupled with stereotactic biopsy procedures gives more accurate surgery remains sometimes incomplete. Digital mammography coupled with stereotactic biopsy procedures gives more accurate results with minimal invasive techniques. The advantages and disadvantages of the advanced breast biopsy intstrumentation results with minimal invasive techniques. The advantages and disadvantages of the advanced breast biopsy intstrumentation (ABBI) procedure versus vacuum biopsy systems are summarized and compared. Either of those systems is highly accepted by the (ABBI) procedure versus vacuum biopsy systems are summarized and compared. Either of those systems is highly accepted by the patients due to the outpatient manner of its application and the convincing results regarding sensitivity, specificity and patients due to the outpatient manner of its application and the convincing results regarding sensitivity, specificity and accuracy of the methods. accuracy of the methods.
    Der Gynäkologe 04/2012; 33(4):309-313.
  • M. C. Fleisch, B. Hanstein, H. G. Bender
    Der Gynäkologe 01/2007; 40(8):591-591.
  • M. C. Fleisch, B. Hanstein, H. G. Bender
    Gynakologe. 01/2007; 40(8):591-591.
  • [show abstract] [hide abstract]
    ABSTRACT: Die dynamische MRT-Untersuchung der Brust ist eine wichtige Ergnzungsuntersuchung zur Rntgenmammographie und Mammasonographie geworden. Die Sensitivitt liegt zwischen 90 und 100%. Das Indikationsspektrum ist nach dem heutigen Kenntnisstand eng zu stellen und die MR-Mammographie sollte am Ende der Diagnosekette stehen; sie ersetzt keineswegs die Mammographie oder die Sonographie. Klassische Indikationen fr die MR-Mammographie sind z.B. Differenzierung zwischen Rezidiv und Narbe in der Nachsorge, CUP-Syndrom, properative Abklrung bei Mammakarzinom vor geplanter BET und Monitoring bei neoadjuvanter Chemotherapie. Zur jhrlichen Frherkennung bei Hochrisikopatientinnen ist sie wahrscheinlich sinnvoll einsetzbar. Dieser Beitrag wird einen berblick ber die wichtigsten Strken, Schwchen, Fehlerquellen und Kontraindikationen der MR-Mammographie geben.Dynamic magnetic resonance imaging (MRI) of the breast has become an important supplementary diagnostic tool to differentiate diseases of the breast, showing a sensitivity ranging from 90% to 100%. Dynamic breast MRI should be performed in special cases as the last examination in the diagnostic chain. It does not replace mammography or sonography. Classical indications for dynamic breast MRI are the differentiation between scar tissue and recurrent disease after breast conserving therapy, carcinoma of an unknown primary, preoperative local staging before breast conserving therapy and monitoring by neoadjuvant chemotherapy. The additional yearly dynamic breast MRI in a high risk population for breast cancer seems useful. This article provides an overview of the most important advantages, disadvantages, pitfalls and contraindications of dynamic MRI of the breast.
    Der Gynäkologe 06/2006; 39(7):524-532.
  • Gynakologe. 01/2006; 39(7):524-532.
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: The influence of 17beta-estradiol (E2), tamoxifen (TAM) and raloxifen (RLX) on the proliferation of breast (BC) and endometrial carcinoma cell lines (EC) and the expression of different compounds of the estrogen receptor (ER)-transactivation machinery were studied. E2 stimulated the proliferation of BC, but had no effect on the EC. TAM showed a biphasic effect on ER-positive cell lines. RLX showed an antagonistic suppression or no effect. The expression of ERalpha was down-regulated by E2, but not affected by selective estrogen receptor modulators. ERbeta and progesterone receptor expressions were up-regulated by E2, TAM and OHT. This supports the hypothesis that ERbeta expression is also regulated via the ERalpha-pathway. The steroid receptor coactivator (SRC) AIB1 expression was slightly decreased by E2 but not by antiestrogens (antiE). TIF2 expression was increased by E2, TAM and RLX, but SRC-1 expression was not. In comparison, the expressions of ERbeta and progesterone receptor were strongly influenced by antiE, while the expression of SRCs was only slightly affected.
    Anticancer research 01/2006; 26(1B):735-44. · 1.71 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: The relevance of estrogens for cognition in older women is still debated. In this double-blind experiment hysterectomized women (age 58-75 years) received placebo (n = 13), estradiol (n = 12) or estradiol/progesterone (n = 10) treatment. Cognitive testing (nine different tests) took place at baseline, after 4 and 24 weeks of treatment. Strong hormone increases occurred in both active treatment groups. However, no beneficial effects in any of the cognitive tests could be detected. This study, therefore, does not support the notion that treatment with sex hormones has beneficial effects on cognition in older hysterectomized women. The human brain might loose its responsiveness to gonadal steroids with aging or prolonged hormone depletion.
    Neurobiology of Aging 08/2005; 26(7):1029-33. · 6.17 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The CD44 v7/8 splice variant that is frequently expressed in cervical carcinoma and rarely expressed in normal tissues displays promising properties as a target antigen for cancer immune therapy. In this study, cytotoxic T lymphocytes (CTLs) were genetically engineered to gain CD44v7/8 target specificity. Clone 96 (Cl96), an established murine cytotoxic T-cell line, and naïve murine T cells were retrovirally transduced with a fusion gene construct encoding for the single chain fragment scFv of the monoclonal antibody VFF17 and for the zeta chain of the T-cell receptor (TCR). The therapeutic potential of genetically engineered T cells was tested in vitro and in vivo. Surface expression of the chimeric TCR on infected Cl96 and naïve T cells was shown by FACS analysis. CD44v7/8-positive target cells were efficiently lysed by transduced Cl96 and naïve T cells, demonstrating the functionality and specificity of the chimeric TCR. In a xenograft BALB/c mouse model, efficient growth retardation of CD44v7/8-positive tumours was mediated by genetically engineered Cl96(VFF17)cyYZ cells. We were able to reprogramme the target specificity of recombinant Cl96 and naïve CTLs resulting in efficient cytolysis of CD44v7/8-positive cervical cancer cells. High transduction rates and the specific cytolysis of CD44v7/8-redirected CTLs are promising tools for an immune gene therapy approach for advanced cervical cancer.
    Cancer Immunology and Immunotherapy 02/2005; 54(1):51-60. · 3.64 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Evidence for a role of ovarian factors in the growth of metastatic breast cancer was first recognized over 100 years ago. Today, anti-estrogens are central to the treatment of breast cancer of all stages. We now understand that the action of estrogen is mediated by the estrogen receptors (ER) which are members of the nuclear receptor family of ligand-regulated transcription factors. In this article we review the molecular mechanisms through which ER activates transcription of target genes and through which available anti-estrogens mediate their therapeutic effects. We discuss possible mechanisms of failure of treatment with current anti-estrogens and how newer anti-estrogens under development attempt to address these problems. In addition an expanded view of the molecular mechanisms of estrogen action is leading to the development of novel selective ER modulators or SERMs.
    European Journal of Endocrinology 04/2004; 150(3):243-55. · 3.14 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The physiological effects of progesterone are mediated by the progesterone receptor (PR) isoforms PRA and PRB, transcribed from a single gene, under control of two distinct promoters. Both the isoforms display different, promoter- and cell line-specific transactivation properties. Upregulation of both isoforms in response to estradiol stimulation has been described, although the two promoters contain no classical estrogen response element (ERE). Therefore, we decided to investigate the regulation of PRB-expression through distinct estrogen receptor (ER)-isoforms: ERalpha and ERbeta We demonstrate, that in HeLa cells treated with E2, PRB promoter activity was enhanced (five-fold) by ERalpha, but not by ERbeta. ERbeta was also unable to stimulate activity of the PRB promoter in BT20 and Ishikawa cells, where ERalpha induced reporter activity by two-fold. Deletion of the AF1-but not AF2 domain from ERalpha resulted in loss of the transactivation potential in all cell lines tested. Furthermore, in BT20 cells deletion of the AF2 domain of ERalpha resulted in stronger transcriptional activation than that mediated through wild-type ERalpha. In SK-BR-3 cells both ERs repressed PRB promoter activity and this repression was enhanced by co-transfection of SRC1. However, strong estrogen-dependent stimulation was observed after deletion of AF2. We conclude that PRB expression is stimulated by ERalpha but not ERbeta in an unique, AF1-dependent but AF2-independent mechanism.
    The Journal of Steroid Biochemistry and Molecular Biology 03/2004; 88(2):131-42. · 3.98 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Die Zellproliferation und das berleben maligner Zellen werden durch intrazellulre Signalbertragungsmolekle gesteuert. Diese Molekle werden wiederum durch parakrine und/oder autokrine sowie hormonelle Stimuli aktiviert. Einer der wichtigsten Signalbertragungswege bei gynkologischen Tumoren ist u.a. die MAP-Kinase. Sie wird durch den Rezeptor fr den epidermalen Wachstumsfaktor aktiviert. HER2-monoklonale Antikrper und Gefitinib (Iressa) stellen Beispiele fr spezifische Signalbertragungshemmer dar, die derzeit klinisch erfolgreich bei Mammakarzinompatientinnen eingesetzt werden.The proliferation and survival of malignant cells depend on intracellular signal transduction molecules. These molecules may be activated through paracrine and/or autocrine as well as hormonal stimulation. One of the most important signal transduction pathways in gynecologic malignancies is the MAP kinase pathway, which may be activated through the epidermal growth factor receptor. HER2 monoclonal antibodies and Gefitinib (Iressa) are examples of specific signal transduction inhibitors that are being used in clinical practice in breast cancer patients.
    Der Gynäkologe 02/2004; 37(3):215-221.
  • Gynakologe. 01/2004; 37(3):215-221.
  • [show abstract] [hide abstract]
    ABSTRACT: Herpes gestationis (HG) is a rare, recurrent, pruritic, vesicobullous dermatosis occurring predominantly in pregnancy and seldom in early puerperium. Reports of the association of HG with choriocarcinoma are extremely rare and this case highlights such a possible link. This case focuses on the late postpartal manifestation of HG being associated with metastatic high-risk choriocarcinoma. Direct immunofluorescence was used to verify the diagnosis of HG. Symptomatic therapy with corticosteroids and antihistamines alleviated the pruritic symptoms associated with HG, but only the recurrent course of chemotherapy for the choriocarcinoma resulted in complete disappearance of all signs and symptoms of the HG. The time course of this case highlights once again the possible association of HG as a paraneoplastic syndrome of choriocarcinoma.
    Gynecologic Oncology 06/2003; 89(2):334-7. · 3.93 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Viral vector systems are the most commonly used gene transfer tools for clinical gene therapy. However, lipofection systems are potential alternatives because of lower immunogenicity and easier cGMP production, but in vivo stability and transduction efficacy need to be improved. Therefore, we investigated gene transduction efficiency of our novel cGMP cationic lipids, CCQ22 and CCQ32, by FACS analysis. Toxicity analysis was performed to determine the cytotoxic side effects of the novel lipids. To evaluate the stability of the compounds in the context of local delivery to patients with intraperitoneally metastatic ovarian cancer, gene transfer was also tested in the presence of malignant ascites. Our novel cGMP standard lipids mediated gene transfer rates of more than 50%. However, for most cell lines cytotoxic side effects were similar to our reference lipofection system. In general, ascites had no major influence on gene transduction rates with the novel lipids. Our results suggest that CCQs may compare favorably with commercially available lipofection systems. These promising results facilitate further analysis of the compounds.
    Cancer Gene Therapy 05/2003; 10(4):312-7. · 2.95 Impact Factor
  • Bettina Hanstein, M W Beckmann, H G Bender
    [show abstract] [hide abstract]
    ABSTRACT: Estrogens play a crucial role in the regulation of the physiology of breast tissue and endometrium. Furthermore, estrogen has been implicated in the initiation and progression of neoplasms of these tissues. Estrogens mediate their effects through various estrogen receptor isoforms and isotypes. In breast tissue and in the endometrium the classical estrogen receptor ERalpha represents the mainly expressed ER isoform, whereas in the ovary the alternative estrogen receptor ERbeta is predominantly expressed. This review briefly describes the structure, function and expression of these receptors with special regard to endometrial cancer. Recent data indicate that alterations of the physiological ERalpha/ERbeta ratio in endometrial cancer correlates with poor clinical outcome. The potential clinical relevance of differential ER-isotype expression is also discussed with respect to an antihormonal therapy.
    Zentralblatt für Gynäkologie 02/2002; 124(1):17-9.
  • [show abstract] [hide abstract]
    ABSTRACT: Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas.
    Hormone and Metabolic Research 09/2001; 33(8):451-7. · 2.15 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Steroid receptor coactivator 3 (SRC3) functions as a coactivator for nuclear receptor mediated transcriptional activation. It binds to nuclear receptors in a ligand-dependent fashion and recruits other factors such as CBP and p300 to the transactivation complex. Due to its function as activator of nuclear receptors, overexpression of SRC3 might enhance their effects. Gene amplification is a common mechanism that causes overexpression, already described for oncogenes like c-erbB2, c-myc and int2. In this study, SRC3 gene amplification and expression levels were analyzed in 127 sporadic breast carcinomas, 30 endometrial carcinomas and different cell lines (MCF7, HeLa, Ishikawa, T47D, BT-20, SK-BR-3, HEC-1a, RL 95-2, OVCAR3 and A-431). To determine gene amplification and mRNA expression levels, quantitative differential PCR and RT-PCR were performed in combination with fluorescent DNA technology. Gene amplification was not found in any of the breast and endometrial carcinomas, but was found in the carcinoma cell lines MCF7 (10-fold) and HeLa (3-fold). SRC3 overexpression was detected in 13% (3/23) of breast carcinomas and 17% (5/30) of endometrial carcinomas, as well as in MCF7 and HeLa cells. Thus, SRC3 overexpression found in breast and endometrial tumors is not caused by SRC3 gene amplification. A carcinogenic potential provided by SRC3 overexpression has to be elucidated in further studies.
    Hormone and Metabolic Research 04/2001; 33(3):121-6. · 2.15 Impact Factor
  • Source
    Breast Cancer Research 01/2001; 3:1-1. · 5.33 Impact Factor
  • Reproduktionsmedizin 01/2001; 17(4):194-205.
  • Source
    Breast Cancer Research 01/2001; 3:1-1. · 5.33 Impact Factor

Publication Stats

571 Citations
59.68 Total Impact Points

Institutions

  • 2002–2007
    • Heinrich-Heine-Universität Düsseldorf
      • Frauenklinik
      Düsseldorf, North Rhine-Westphalia, Germany
  • 2001–2003
    • Universitätsklinikum Düsseldorf
      Düsseldorf, North Rhine-Westphalia, Germany
  • 1996–1999
    • Dana-Farber Cancer Institute
      Boston, Massachusetts, United States